Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Sell at BidaskClub

BidaskClub upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday, BidAskClub reports.

ABEO has been the topic of a number of other research reports. ValuEngine upgraded Abeona Therapeutics from a sell rating to a hold rating in a report on Tuesday, March 5th. HC Wainwright restated a buy rating on shares of Abeona Therapeutics in a research note on Monday, May 6th. Zacks Investment Research upgraded Abeona Therapeutics from a sell rating to a hold rating in a research note on Wednesday, March 20th. Maxim Group restated a buy rating on shares of Abeona Therapeutics in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald restated a buy rating and set a $29.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $24.83.

Shares of Abeona Therapeutics stock opened at $5.17 on Tuesday. Abeona Therapeutics has a twelve month low of $5.02 and a twelve month high of $17.25. The company has a quick ratio of 3.35, a current ratio of 3.35 and a debt-to-equity ratio of 0.06.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.06. Abeona Therapeutics had a negative return on equity of 45.58% and a negative net margin of 960.91%. The firm had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $1.66 million. On average, analysts anticipate that Abeona Therapeutics will post -1.6 earnings per share for the current year.

In other Abeona Therapeutics news, Director Stephen B. Howell purchased 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average price of $7.77 per share, for a total transaction of $31,080.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at approximately $46,620. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Stefano Buono purchased 70,000 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $7.80 per share, for a total transaction of $546,000.00. Following the purchase, the director now owns 20,980 shares of the company’s stock, valued at approximately $163,644. The disclosure for this purchase can be found here. Insiders own 33.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA lifted its stake in shares of Abeona Therapeutics by 21,590.0% in the first quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 6,477 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in Abeona Therapeutics by 247.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,194 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 7,258 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Abeona Therapeutics by 18.2% in the first quarter. The Manufacturers Life Insurance Company now owns 12,589 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,935 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Abeona Therapeutics by 178.9% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 18,237 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 11,698 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in Abeona Therapeutics by 23.7% in the fourth quarter. SG Americas Securities LLC now owns 22,720 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 4,351 shares during the last quarter. Institutional investors and hedge funds own 63.61% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Recommended Story: What is the market perform rating?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.